Emerging biomarkers for immune checkpoint inhibition in lung cancer

被引：73

作者：

Cyriac, George ^{[1
]}

Gandhi, Leena ^{[1
]}

机构：

[1] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY 10016 USA

来源：

SEMINARS IN CANCER BIOLOGY | 2018年 / 52卷

关键词：

PD-1; PD-L1; Immunotherapy; Checkpoint inhibitors; Biomarkers; Non-small cell lung cancer; Tumor mutational burden; Microbiome; TUMOR-INFILTRATING LYMPHOCYTES; RANDOMIZED CONTROLLED-TRIAL; PD-1; BLOCKADE; OPEN-LABEL; SQUAMOUS-CELL; SOLID TUMORS; ACQUIRED-RESISTANCE; STANDARDIZED METHOD; ENDOMETRIAL CANCER; 1ST-LINE TREATMENT;

D O I：

10.1016/j.semcancer.2018.05.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibition with anti-PD-1 therapy has been notably successful in non-small cell lung cancer (NSCLC) and changed standard practice in multiple settings. However, despite some durable benefits seen, the majority of unselected patients with NSCLC fail to respond to checkpoint inhibitors. Patient selection is crucial and will become even more important in the development of combination therapies with immune checkpoint inhibitors. PD-L1 expression by immunohistochemistry (IHC) has emerged as the most commonly used clinical biomarker of response and overall tumor mutational burden (TMB) is being explored as a clinical biomarker. However, both are hampered by being imperfect predictors of response and both can be dynamic during the course of illness. In this review, we will discuss the development of PD-L1 expression as a biomarker as well as the ongoing emergence of other genomic and proteomic markers that can help refine our use of immunotherapies to maximize benefit in the most patients.

引用

页码：269 / 277

页数：9

共 80 条

[1] Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].

Anagnostou, Valsamo ;

Smith, Kellie N. ;

Forde, Patrick M. ;

Niknafs, Noushin ;

Bhattacharya, Rohit ;

White, James ;

Zhang, Theresa ;

Adleff, Vilmos ;

Phallen, Jillian ;

Wali, Neha ;

Hruban, Carolyn ;

Guthrie, Violeta B. ;

Rodgers, Kristen ;

Naidoo, Jarushka ;

Kang, Hyunseok ;

Sharfman, William ;

Georgiades, Christos ;

Verde, Franco ;

Illei, Peter ;

Li, Qing Kay ;

Gabrielson, Edward ;

Brock, Malcolm V. ;

Zahnow, Cynthia A. ;

Baylin, Stephen B. ;

Scharpf, Robert B. ;

Brahmer, Julie R. ;

Karchin, Rachel ;

Pardoll, Drew M. ;

Velculescu, Victor E. .

CANCER DISCOVERY, 2017, 7 (03) :264-276

[2] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].

Anderson, Ana C. ;

Joller, Nicole ;

Kuchroo, Vijay K. .

IMMUNITY, 2016, 44 (05) :989-1004

[3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[4] Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study [J].

Antonia, Scott ;

Goldberg, Sarah B. ;

Balmanoukian, Ani ;

Chaft, Jamie E. ;

Sanborn, Rachel E. ;

Gupta, Ashok ;

Narwal, Rajesh ;

Steele, Keith ;

Gu, Yu ;

Karakunnel, Joyson J. ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2016, 17 (03) :299-308

[5] Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? [J].

Apetoh, L. ;

Ladoire, S. ;

Coukos, G. ;

Ghiringhelli, F. .

ANNALS OF ONCOLOGY, 2015, 26 (09) :1813-1823

[6] The IFN gamma receptor: A paradigm for cytokine receptor signaling [J].

Bach, EA ;

Aguet, M ;

Schreiber, RD .

ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :563-&

[7] Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers [J].

Blakely, Collin M. ;

Watkins, Thomas B. K. ;

Wu, Wei ;

Gini, Beatrice ;

Chabon, Jacob J. ;

McCoach, Caroline E. ;

McGranahan, Nicholas ;

Wilson, Gareth A. ;

Birkbak, Nicolai J. ;

Olivas, Victor R. ;

Rotow, Julia ;

Maynard, Ashley ;

Wang, Victoria ;

Gubens, Matthew A. ;

Banks, Kimberly C. ;

Lanman, Richard B. ;

Caulin, Aleah F. ;

St John, John ;

Cordero, Anibal R. ;

Giannikopoulos, Petros ;

Simmons, Andrew D. ;

Mack, Philip C. ;

Gandara, David R. ;

Husain, Hatim ;

Doebele, Robert C. ;

Riess, Jonathan W. ;

Diehn, Maximilian ;

Swanton, Charles ;

Bivona, Trever G. .

NATURE GENETICS, 2017, 49 (12) :1693-+

[8] PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].

Blank, C ;

Brown, I ;

Peterson, AC ;

Spiotto, M ;

Iwai, Y ;

Honjo, T ;

Gajewski, TF .

CANCER RESEARCH, 2004, 64 (03) :1140-1145

[9] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[10] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

← 1 2 3 4 5 6 7 8 →